$IMVT

Van Tuyl Christopher sold $48K of IMVT

Van Tuyl Christopher (Chief Legal Officer) sold 1,206 shares of Immunovant, Inc. (IMVT) at an average of $39.55 ($39.53–$39.99) across 2 trades on 2026-07-08.

Original reporting
SEC EDGAR · Van Tuyl Christopher
Published Jul 10, 2026, 8:13 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 10, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IMVT
Neutral
medium confidence
Mentioned
$IMVT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMVTNeutralLow
01

Why it matters

The disclosure updates insider ownership levels following an open-market sale by the Chief Legal Officer, but it does not include any new guidance, trial results, regulatory actions, or deal terms.

02

Market read

Primarily useful for monitoring insider activity trends; not a standalone trading catalyst.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-planned personal liquidity needs; the filing does not indicate intent beyond the transaction code and price/volume details.

Relevance 3/10Novelty 2/10Timing: after-hours, SEC Form 4 filed 2026-07-10 for a 2026-07-08 sale

Background

The article is a primary-source SEC Form 4 insider transaction for Immunovant, Inc. (IMVT).

Company-level read

Ticker impact

$IMVTNeutralMedium confidence
Context

Immunovant’s Chief Legal Officer filed a Form 4 selling 1,206 shares in open-market trades at about $39.55 per share on 2026-07-08.

Expected impact

Likely limited near-term impact; treat as routine insider activity unless follow-on filings show sustained selling or other disclosures emerge.

Evidence & confidence

The filing provides transaction size, price range, and post-sale holdings, but no new operational, regulatory, or financial information about Immunovant.

Market effects

None; this is company-specific insider transaction data without sector-wide signal.

None.

None.

Counterpoint

If the absence of a 10b5-1 plan is accurate, some traders may interpret it as higher near-term risk, but the article provides no supporting fundamental deterioration.

Key entities

  • Immunovant, Inc.

    Subject of the Form 4 insider transaction; ticker IMVT.

  • Van Tuyl Christopher

    Chief Legal Officer who sold 1,206 shares across two trades on 2026-07-08.

Related articles

$IMVTMed

Immunovant, Inc. (IMVT): Results of Operations and Financial Condition

Immunovant, Inc. (IMVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991202686.htm EX-99.1 Document Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 • All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD),

$IMVTMedAI 9/10

H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data

H.C. Wainwright raised its Immunovant (IMVT) price target to $40 from $35 and kept a Buy rating after positive Phase 2 rheumatoid arthritis data, citing high response rates and suggesting FcRn differs from JAK/TNF therapies. It increased IMVT-1402 success odds to 55% (from 30%) and EV sales multiple to 10x (from 9x). BofA also lifted its target to $43 and peak sales forecast for IMVT-1402 to $6.8B from $5.5B.